Z. S. Shprakh, A. R. Kovaleva, E. V. Sanarova, D. A. Kozin, L. L. Nikolaeva
{"title":"酪氨酸激酶抑制剂脂质体剂型的研制","authors":"Z. S. Shprakh, A. R. Kovaleva, E. V. Sanarova, D. A. Kozin, L. L. Nikolaeva","doi":"10.1134/S263516762560066X","DOIUrl":null,"url":null,"abstract":"<p>Pazopanib is a multitargeted tyrosine kinase inhibitor that suppresses angiogenesis and proliferation of tumor cells. To increase its bioavailability, a model of a liposomal dosage form of pazopanib is developed and its main pharmaceutical and technological characteristics are determined. It is found that a composition including the active substance, egg phosphatidylcholine, cholesterol, and poly(ethylene glycol) lipid in a mass ratio of 1 : 75 : 7.5 : 0.75 possesses the best properties (size, polydispersity index, and surface charge). To determine the pazopanib concentration in model mixtures, ultraviolet (UV) spectrophotometry is used, which demonstrates the specificity of the method and its linearity (the ability to obtain results within a specified range that are directly proportional to the concentration of the analyte in the sample). The liposomal dispersion is stabilized by lyophilization, and a 10%-aqueous sucrose solution is selected as a cryoprotectant. Pazopanib in the final product is determined by high-performance liquid chromatography. The stability of the lyophilized liposomal dosage form for six months at a storage temperature of no higher than –18°C is shown.</p>","PeriodicalId":716,"journal":{"name":"Nanotechnologies in Russia","volume":"20 3","pages":"366 - 372"},"PeriodicalIF":0.8000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"On the Pharmaceutical Development of a Liposomal Dosage Form of a Tyrosine Kinase Inhibitor\",\"authors\":\"Z. S. Shprakh, A. R. Kovaleva, E. V. Sanarova, D. A. Kozin, L. L. Nikolaeva\",\"doi\":\"10.1134/S263516762560066X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Pazopanib is a multitargeted tyrosine kinase inhibitor that suppresses angiogenesis and proliferation of tumor cells. To increase its bioavailability, a model of a liposomal dosage form of pazopanib is developed and its main pharmaceutical and technological characteristics are determined. It is found that a composition including the active substance, egg phosphatidylcholine, cholesterol, and poly(ethylene glycol) lipid in a mass ratio of 1 : 75 : 7.5 : 0.75 possesses the best properties (size, polydispersity index, and surface charge). To determine the pazopanib concentration in model mixtures, ultraviolet (UV) spectrophotometry is used, which demonstrates the specificity of the method and its linearity (the ability to obtain results within a specified range that are directly proportional to the concentration of the analyte in the sample). The liposomal dispersion is stabilized by lyophilization, and a 10%-aqueous sucrose solution is selected as a cryoprotectant. Pazopanib in the final product is determined by high-performance liquid chromatography. The stability of the lyophilized liposomal dosage form for six months at a storage temperature of no higher than –18°C is shown.</p>\",\"PeriodicalId\":716,\"journal\":{\"name\":\"Nanotechnologies in Russia\",\"volume\":\"20 3\",\"pages\":\"366 - 372\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanotechnologies in Russia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1134/S263516762560066X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Engineering\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanotechnologies in Russia","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1134/S263516762560066X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Engineering","Score":null,"Total":0}
On the Pharmaceutical Development of a Liposomal Dosage Form of a Tyrosine Kinase Inhibitor
Pazopanib is a multitargeted tyrosine kinase inhibitor that suppresses angiogenesis and proliferation of tumor cells. To increase its bioavailability, a model of a liposomal dosage form of pazopanib is developed and its main pharmaceutical and technological characteristics are determined. It is found that a composition including the active substance, egg phosphatidylcholine, cholesterol, and poly(ethylene glycol) lipid in a mass ratio of 1 : 75 : 7.5 : 0.75 possesses the best properties (size, polydispersity index, and surface charge). To determine the pazopanib concentration in model mixtures, ultraviolet (UV) spectrophotometry is used, which demonstrates the specificity of the method and its linearity (the ability to obtain results within a specified range that are directly proportional to the concentration of the analyte in the sample). The liposomal dispersion is stabilized by lyophilization, and a 10%-aqueous sucrose solution is selected as a cryoprotectant. Pazopanib in the final product is determined by high-performance liquid chromatography. The stability of the lyophilized liposomal dosage form for six months at a storage temperature of no higher than –18°C is shown.
期刊介绍：
Nanobiotechnology Reports publishes interdisciplinary research articles on fundamental aspects of the structure and properties of nanoscale objects and nanomaterials, polymeric and bioorganic molecules, and supramolecular and biohybrid complexes, as well as articles that discuss technologies for their preparation and processing, and practical implementation of products, devices, and nature-like systems based on them. The journal publishes original articles and reviews that meet the highest scientific quality standards in the following areas of science and technology studies: self-organizing structures and nanoassemblies; nanostructures, including nanotubes; functional and structural nanomaterials; polymeric, bioorganic, and hybrid nanomaterials; devices and products based on nanomaterials and nanotechnology; nanobiology and genetics, and omics technologies; nanobiomedicine and nanopharmaceutics; nanoelectronics and neuromorphic computing systems; neurocognitive systems and technologies; nanophotonics; natural science methods in a study of cultural heritage items; metrology, standardization, and monitoring in nanotechnology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
